IGM Biosciences
Latest round
- Series C
Last raised
- Jul 2019
Total raised
- $102M
Investors
- 5
About IGM Biosciences
IGM Biosciences, Inc.Founded in 2010 and headquartered in Mountain View, US, IGM Biosciences, Inc. specializes in creating engineered therapeutic IgM antibodies.7 mn to date. Fred Schwarzer serves as the CEO, leading the organization through various strategic initiatives.IGM Biosciences specializes in developing a novel class of antibody therapeutics aimed at treating autoimmune and inflammatory diseases. Their core offerings are engineered therapeutic IgM antibodies, which leverage superior binding capabilities compared to conventional IgG antibodies. These antibodies are being designed to provide new treatment options for patients with autoimmune disorders.47 mn. The company is also targeting the expansion of its market reach into new geographic areas, with an emphasis on enhancing its presence in North America and Europe, as it prepares for the launch of upcoming products designed to address unmet medical needs in the field of immunology.
Who invested in IGM Biosciences
5 investors across 1 round
See all investors in IGM Biosciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series C
Jul 8, 2019
Amount
$102M
Investors
Questions about IGM Biosciences
Who invested in IGM Biosciences?
IGM Biosciences has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has IGM Biosciences raised?
IGM Biosciences has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did IGM Biosciences last raise money?
IGM Biosciences's most recent round on record is a Series C, in Jul 2019.
What does IGM Biosciences do?
IGM Biosciences is a biotechnology company.
Where is IGM Biosciences headquartered?
IGM Biosciences is headquartered in Mountain View, US.
Which VCs invest in companies like IGM Biosciences?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at IGM Biosciences's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like IGM Biosciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.